Denosumab does not delay nonvertebral fracture healing

December 19, 2012
Denosumab does not delay nonvertebral fracture healing
Denosumab does not appear to delay fracture healing or contribute to other complications when used to treat postmenopausal women with osteoporosis, according to research published in the Dec. 5 issue of The Journal of Bone & Joint Surgery.

(HealthDay)—Denosumab does not appear to delay fracture healing or contribute to other complications when used to treat postmenopausal women with osteoporosis, according to research published in the Dec. 5 issue of The Journal of Bone & Joint Surgery.

To examine the impact of administration on , Silvano Adami, M.D., Ph.D., of the University of Verona in Italy, and colleagues conducted a pre-planned analysis of the three-year, placebo-controlled FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every Six Months) study. The study included (aged 60 to 90 years) with who received either 60 mg of denosumab (3,902 ) or placebo (3,906 women) subcutaneously once every six months for three years.

The researchers identified 386 nonvertebral fractures among 303 denosumab-treated women and 465 fractures among 364 placebo-treated women, of which 199 fractures were treated surgically (79 and 120 in the denosumab and placebo groups, respectively). Seven individuals experienced delayed healing, including one with subsequent nonunion; two of these women were treated with denosumab and five received placebo. None of the women who experienced delayed fracture healing or nonunion had received denosumab within six weeks of the fracture. In 2 percent of the denosumab group and 5 percent of the placebo group there was a complication associated with the fracture or intervention.

"In the thirty-six-month FREEDOM trial, there was no evidence that denosumab treatment delayed healing or contributed to complications related to a nonvertebral fracture or its management," the authors write. "However, since the exact timing of completion of fracture healing could not be determined, it remains theoretically possible that denosumab might delay or speed fracture healing."

The study was funded by Amgen, which developed denosumab. Several authors disclosed financial ties to an entity in the biomedical arena.

Explore further: Denosumab superior to zoledronic acid for breast cancer patients with bone metastases

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Denosumab superior to zoledronic acid for breast cancer patients with bone metastases

August 14, 2012
Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the bones compared with zoledronic acid, while also maintaining health-related quality of life, ...

Study shows bone metastases treatment can improve overall survival

November 15, 2012
It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent ...

Denosumab delays development of prostate cancer bone metastasis

November 16, 2011
An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer. The study, receiving Online First ...

Denosumab reduces burden of giant-cell tumor of the bone

September 21, 2012
Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according ...

Recommended for you

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.